Evolent Health Reports 22.8% Revenue Decline in Q3 2025

Evolent Health, Inc. reported a significant decline in its financial performance for the third quarter of 2025, with total revenue decreasing by 22.8% to $479.5 million compared to $621.4 million in the same period last year. For the nine months ended September 30, 2025, revenue fell 26.2% to $1.41 billion from $1.91 billion in 2024. The decrease was primarily attributed to contractual updates with key customers, including a $76.5 million transition of a customer from the Performance Suite to the Specialty Technology and Services Suite, and a $94.7 million reduction related to the narrowing of scope for certain Performance Suite customers. Despite these challenges, the company noted a $46.3 million growth in other contracts within the Performance Suite and Specialty Technology and Services Suite.

Evolent's operating expenses also saw a notable reduction, with total operating expenses decreasing by 24.9% to $478.6 million for the third quarter, driven by a 29.8% drop in cost of revenue, which amounted to $379.8 million. This decline in costs was largely due to lower claims expenses associated with the aforementioned customer transitions. However, selling, general, and administrative expenses increased by 15.7% to $77.6 million, primarily due to higher personnel costs. The company reported an operating income of $886, a significant improvement from a loss of $16.3 million in the prior year.

In terms of strategic developments, Evolent Health is in the process of selling its subsidiary, Evolent Care Partners Holding Company, for $100 million, with the transaction expected to close in the fourth quarter of 2025. This sale is part of the company's broader strategy to streamline operations and focus on its core business areas. Additionally, Evolent completed the acquisition of Machinify, Inc., a software platform leveraging artificial intelligence, for $28.5 million, which is anticipated to enhance its service offerings.

Operationally, Evolent reported a decrease in its average Lives on Platform, which fell to 6.5 million from 6.9 million year-over-year. The company also noted a decline in its average PMPM (per member per month) fees for the Performance Suite, which dropped to $14.77 from $20.97. The company’s customer base remains concentrated, with Molina Healthcare, Inc. representing 25.7% of revenue for the quarter, up from 14.9% in the previous year. This concentration poses risks, as the loss or renegotiation of contracts with significant partners could adversely affect financial results.

Looking ahead, Evolent Health expressed cautious optimism, stating that it believes it has sufficient liquidity to meet its operational needs for at least the next twelve months, with $116.7 million in cash and cash equivalents as of September 30, 2025. However, the company acknowledged ongoing challenges, including rising medical claims costs and regulatory uncertainties stemming from recent healthcare legislation, which could impact future performance. The company is actively monitoring these dynamics and their potential effects on its business operations and financial condition.